Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).

L Beex; C Rose; H Mouridsen; J Jassem; M Nooij; J Estape; R Paridaens; M Piccart; T Gorlia; S Lardenoije

doi:10.1016/j.ejca.2006.08.020

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).

Identifier:nobleid.org/w1/20260515/FF4AA7DA

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FF4AA7DA.svg?ark=w1%2F20260515%2FFF4AA7DA)](https://nobleid.org/work/w1/20260515/FF4AA7DA)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).

Identifier:nobleid.org/w1/20260515/FF4AA7DA

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FF4AA7DA.svg?ark=w1%2F20260515%2FFF4AA7DA)](https://nobleid.org/work/w1/20260515/FF4AA7DA)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work